Exhibit 10.3.3


 


Certain identified information has been excluded from the exhibit
pursuant to Item 601(a)(6) of Regulation S-K due to personal privacy concerns or pursuant to Item 601(b)(10)(iv) because it is both not
material and is the type of information that the registrant treats as private or confidential. Redacted information is indicated by: [***]


 





 


 


	February 13, 2019	UBC File: F16-05805


 


VIA EMAIL


 


Dr. Elliot Goldstein

President and CEO

ProMis Neurosciences, Inc.

Suite 200, 1920 Yonge Street

Toronto, ON

M4S 3E2

[***]


 


 


Dear Dr. Goldstein,


 


	Re:	Collaborative Research Agreement between The University of British Columbia (“UBC”) and Vancouver Coastal Health Authority (“Hospital”) (UBC and Hospital collectively, the “Institution”) and ProMis Neurosciences, Inc, (the “Sponsor”) effective April 1, 2016 and amended by Amendment No. 1 dated December 13, 2017 and Amendment No.2 dated July 5, 2018 (the “Agreement”)



Amendment No. 3



 


 


The Institution and Sponsor have executed the Agreement and hereby
agree to amend the Agreement as follows:


 


Article 4.1 shall be revised and read as follows: 


 


“4.1
The Parties understand and agree that, subject to Article 4.3, and excluding any intellectual property related costs under Section 7,
the total costs to the Sponsor hereunder will be $[***] (Canadian funds). The Parties acknowledge that any budget categories that may
be described in the Project are estimates only and that changes from category to category may be made at the Institution’s discretion.
The Sponsor will pay to UBC the amounts of the following due dates:


 


	 	1)	Amount already received by UBC	 	$[***]


 


	 	2)	Amount due upon signature of this Amendment No. 3	 	$[***]


 


	 	3)	June 1, 2019	 	$[***]


 


	 	4)	September 1, 2019	 	$[***]


 


	 	5)	December 1, 2020	 	$[***]


 


	 	6)	March, 2020	 	$[***]


 


	 	7)	June 1, 2020	 	$125,000


 


	 	8)	September 1, 2020	 	$125,000


 


	 	9)	December 1, 2020	 	$125,000


 


All other terms and conditions
of the Agreement will remain in full force and effect and will continue for the duration of the Agreement. The Agreement and this Amendment
No. 3 will be read together and constitute one agreement.


 


 






     


     


    

 







This Amendment to the Agreement may be signed in counterparts either
through original copies or by facsimile or electronically each of which will be deemed an original and all of which will constitute the
same instrument.


 


Sincerely,


 


/s/ Jacqueline Lee

Jacqueline Lee

Industry Grants Officer


 




     


     


    

 


SIGNED FOR AND ON BEHALF of

THE UNIVERSITY OF BRITISH COLUMBIA

by its authorized signatory:


 


/s/ Mario Kasapi


	Name:	Mario Kasapi




	Title:	Associate Director, UILO




	Date:	March 6, 2019





 


 


SIGNED FOR AND ON BEHALF of

THE UNIVERSITY OF BRITISH COLUMBIA

by its authorized signatory:




/s/ J. P. Heale


	Name:	Dr. J. P. Heale




	Title:	Managing Director, UILO




	Date:	March 6, 2019





 


 


SIGNED FOR AND ON BEHALF of

VANCOUVER COASTAL HEALTH AUTHORITY

by its authorized signatory:




/s/ W. Robert McMaster


	Name:	Dr. W. Robert McMaster, D. Phil.




	Title:	Vice President Research




	Date:	March 7, 2019





 


SIGNED FOR AND ON BEHALF of

PROMIS NEUROSCIENCES, INC. 

by its authorized signatory:



/s/ Elliot Goldstein


	Name:	Elliot Goldstein, MD




	Title:	President & CEO




	Date:	April 15, 2019




 


 


[signature page]



     


     


    

 


Acknowledged by




/s/ Neil Cashman


Dr. Neil Cashman


Principal Investigator

Department of Neurology

Date: March 8, 2019


 


 


[acknowledgement page]